Compare UAMY & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAMY | DMRA |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 1997 | 2020 |
| Metric | UAMY | DMRA |
|---|---|---|
| Price | $10.77 | $26.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $9.44 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 9.9M | 242.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,257,708.00 | N/A |
| Revenue This Year | $219.89 | N/A |
| Revenue Next Year | $104.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 162.80 | N/A |
| 52 Week Low | $1.94 | $16.50 |
| 52 Week High | $19.71 | $28.57 |
| Indicator | UAMY | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 53.98 |
| Support Level | $10.68 | $23.65 |
| Resistance Level | $11.01 | $27.75 |
| Average True Range (ATR) | 0.86 | 2.19 |
| MACD | 0.24 | 0.17 |
| Stochastic Oscillator | 79.36 | 63.08 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.